Quick Answer
Ultragenyx Pharmaceutical Inc. reported Stockholders Equity of -$80.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$80.00M | -131.4% |
| 2024 | $255.00M | -7.3% |
| 2023 | $275.00M | -21.9% |
| 2022 | $352.00M | -61.8% |
| 2021 | $922.56M | -20.1% |
| 2020 | $1.15B | +76.6% |
| 2019 | $653.76M | +7.4% |
| 2018 | $608.91M | +58.8% |
| 2017 | $383.45M | -19.1% |
| 2016 | $473.97M | -10.8% |
| 2015 | $531.09M | +187.2% |
| 2014 | $184.94M | +347.2% |
| 2013 | -$74.82M | -176.6% |
| 2012 | -$27.05M | -239.7% |
| 2011 | -$7.96M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.16M | -97.4% | -93.9% |
| June 30, 2025 | $151.29M | -65.0% | +4.9% |
| March 31, 2025 | $144.25M | +2.8% | -43.5% |
| December 31, 2024 | $255.30M | -7.3% | -26.4% |
| September 30, 2024 | $346.83M | +993.6% | -19.8% |
| June 30, 2024 | $432.42M | +235.1% | +208.3% |
| March 31, 2024 | $140.26M | -36.4% | -49.1% |
| December 31, 2023 | $275.41M | -21.9% | +768.4% |
- Ultragenyx Pharmaceutical Inc. showed a decrease of -131.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Ultragenyx Pharmaceutical Inc.’s stockholders equity has declined by 904.9% (from -$7.96 million to -$80.00 million).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: